Document is current
Any future updates will be listed below
-
Authors
Shi, Ke
Cao, Ke
Yin, Mingzhu
Liu, Can
Xie, Huiqing
Chen, Xiang
Zhou, Jianda
-
Funding
Funding for this research was provided by:
Xiaohe Sci-Tech Talents Special Funding under Hunan Provincial Sci-Tech Talents Sponsorship Program (No.2023TJ-X07)
Hunan Provincial Natural Science Foundation (No.2024JJ5542)
Chinese National key research and development program (No.2022YFC2504700)
Chinese Natural Science Foundation of China (No.81872219)
Hunan Province Major Research Initiative for High-Level Health and Medical Talents (No.R2023045)
- License Information
-
More Information
Article History
Received: 11 May 2025
Accepted: 4 November 2025
First Online: 13 January 2026
Declarations
:
: All patients signed informed consent forms, and the protocols were approved by the Ethics Committee of Xiangya Hospital of Central South University (202308636) and Shanghai Zhuoli Biotechnology Company Ltd (LLSM-15-01). All experimental animals were reviewed and approved by the Ethics Committee of Central South University (XMSB-2023-0013).
: All authors give consent for the publication of manuscript in MOLECULAR CANCER .
: The authors declare no competing interests.
